ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

NCT06902272 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DIAGNOSTIC_TEST: Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay
DRUG: Pembrolizumab
DRUG: Platinum Doublet Chemotherapy

Sponsor

University of Miami